Overview

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Alemtuzumab
Antibodies, Monoclonal
Antilymphocyte Serum
Basiliximab
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Thymoglobulin